|
|
Blood, Vol. 111, Issue 3, 1515-1523, February 1, 2008
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas
Blood Ding et al.
111: 1515
Supplemental materials for: Ding et al
Files in this Data Supplement:
- Document 1. Supplemental methods (PDF, 63.7 KB)
- Table S1. Primary antibodies used in the IHC and IF studies (PDF, 21.5 KB)
- Table S2. Distribution of BCL6 staining scores in GCB and non-GCB groups (PDF, 13.4 KB)
- Table S3. Distribution of PY-STAT3 staining scores in GCB and non-GCB groups (PDF, 13.4 KB)
- Table S4. Sequence of EMSA probes used in Figure 4B (PDF, 37.2 KB)
- Table S5. Source of lymphoma cell lines used in this study* (PDF, 13.4 KB) -
*With the exception of Mutu III, which is a type III Burkitt’s lymphoma cell line, all other listed are DLBCL cell lines
- Figure S1. BrdU pulse-labeling of AG490 treated Ly10 cells (JPG, 65.7 KB)
-
Ly10 cells were exposed to DMSO or 20 µM AG490 for 20 h before BrdU was added to the culture medium to a final concentration of 10 µM. Cells were cultured for another 90 minutes before fixation, staining with FITC-labeled anti-BrdU antibody and, finally, propidium iodide for 30 minutes. Numbers in the boxed areas in the FACS profile indicate the percentages of the BrdU positive S-phase fraction, sub-G1 fraction that is BrdU-positive and BrdU-negative, respectively.
|
|
